Literature DB >> 7617556

Malnutrition and pharmacokinetics of penicillin in Ethiopian children.

P Bolme1, M Eriksson, L Paalzow, G Stintzing, G Zerihun, T Woldemariam.   

Abstract

Penicillin was given to 104 children with different nutritional status, normal, underweight, marasmus and kwashiorkor. Penicillin was given either intravenously, intramuscularly or orally and the plasma concentration was followed at regular times after administration. There was a significantly decreased plasma clearance of penicillin in all malnourished groups compared to the normal weight-for-age group. The half-lives of penicillin were, however, not significantly different between the nutritional groups. This was explained by the fact that also the volume of distribution was decreased in the malnourished group with a net result that the half-life was unchanged. The bioavailability was decreased if penicillin was given to non-fasting individuals. The greatest difference between fasting and non-fasting was seen in the severely malnourished children with marasmus and kwashiorkor. Therefore, it is advised that, if penicillin is given orally to very sick and undernourished children, the dose should be increased and preferably be given in the fasting state.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617556     DOI: 10.1111/j.1600-0773.1995.tb00140.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  9 in total

Review 1.  Antibiotics in severely malnourished children: systematic review of efficacy, safety and pharmacokinetics.

Authors:  Marzia Lazzerini; David Tickell
Journal:  Bull World Health Organ       Date:  2011-05-20       Impact factor: 9.408

2.  Impact of Antibiotic Resistance on Treatment of Pneumococcal Disease in Ethiopia: An Agent-Based Modeling Simulation.

Authors:  Hui-Han Chen; Andrew Stringer; Tadesse Eguale; Gauri G Rao; Sachiko Ozawa
Journal:  Am J Trop Med Hyg       Date:  2019-11       Impact factor: 2.345

Review 3.  A systematic review of pharmacokinetics studies in children with protein-energy malnutrition.

Authors:  Kazeem A Oshikoya; Helen M Sammons; Imti Choonara
Journal:  Eur J Clin Pharmacol       Date:  2010-06-16       Impact factor: 2.953

4.  Lack of a significant change in caffeine metabolism in underweight children as determined by the caffeine breath test.

Authors:  K A Oshikoya; H Sammons; K Smith; I Choonara
Journal:  Arch Dis Child       Date:  2015-04-20       Impact factor: 3.791

Review 5.  Severe acute malnutrition and infection.

Authors:  Kelsey D J Jones; James A Berkley
Journal:  Paediatr Int Child Health       Date:  2014-12       Impact factor: 1.990

6.  Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection.

Authors:  Samuel L M Arnold; Ryan Choi; Matthew A Hulverson; Deborah A Schaefer; Sumiti Vinayak; Rama S R Vidadala; Molly C McCloskey; Grant R Whitman; Wenlin Huang; Lynn K Barrett; Kayode K Ojo; Erkang Fan; Dustin J Maly; Michael W Riggs; Boris Striepen; Wesley C Van Voorhis
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

7.  Guidelines for the treatment of severe acute malnutrition: a systematic review of the evidence for antimicrobial therapy.

Authors:  Phoebe C M Williams; James A Berkley
Journal:  Paediatr Int Child Health       Date:  2018-11       Impact factor: 1.990

8.  A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease: new insights for improved secondary prophylaxis strategies.

Authors:  Robert M Hand; Sam Salman; Nelly Newall; Julie Vine; Madhu Page-Sharp; Asha C Bowen; Katherine Gray; Amy Baker; Joseph Kado; John Joseph; Julie Marsh; James Ramsay; Dianne Sika-Paotonu; Kevin T Batty; Laurens Manning; Jonathan Carapetis
Journal:  J Antimicrob Chemother       Date:  2019-07-01       Impact factor: 5.790

9.  Pathophysiological changes that affect drug disposition in protein-energy malnourished children.

Authors:  Kazeem A Oshikoya; Idowu O Senbanjo
Journal:  Nutr Metab (Lond)       Date:  2009-12-01       Impact factor: 4.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.